Sangita Patel is an Ophthalmology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1176 Main St
Buffalo, NY 14209
Telephone
716-881-7900Registry record last updated 7 Mar 2023.
Clinical trials
- Validating an Inexpensive Practice Model for Microsurgical Skills Training
Sponsor: State University of New York at Buffalo
- Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Sponsor: State University of New York at Buffalo
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Glaukos CorporationProgram year20251 payment
- Alcon Vision LLCProgram year20231 payment
- Alcon Vision LLCProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
66.8%Corticosteroid45.6%Fluorometholone61%Prednisolone Acetate35%Pred Mild4%Part D<11 patientsProstaglandin Analog11.1%Latanoprost83%Lumigan17%Part D<11 patients+ 2 more classes in this area
Anti-infectives
19.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor10.1%Valacyclovir100%Part D≥13 patientsFluoroquinolone Antibacterial5.1%Moxifloxacin100%Part D<11 patients+ 1 more class in this area
Cardiovascular
7.2%Beta blocker7.2%Timolol Maleate100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2018–2026 per NIH RePORTER. The latest:
- Corneal Endothelium – Extracellular Matrix Interactions
State University of New York at Buffalo
FY2026$358,436R01EY034906 - Corneal Endothelium – Extracellular Matrix Interactions
State University of New York at Buffalo
FY2025$358,509R01EY034906
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Ali Bijani
Babol University of Medical Sciences
Hamid Asayesh
Ayatollah Boroujerdi University
John J. Huang
Isfahan University of Medical Sciences
Fotis Topouzis
National University of Singapore
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”